Authors

Reshoring Update: BMS Commits $2.3B to Houston Campus

Bristol Myers Squibb will build a $2.3 billion modular manufacturing campus in Houston, part of a $40 billion five-year US investment pledge.

The First Dose Is Everything: How Noble’s SureStartRx™ Program Improves Adherence and Persistence

Supply Chain Signal: Three Tariff Deadlines Reshaping Pharma Manufacturing

Episode 2 of Supply Chain Signal breaks down the July 31 and September 29 Section 232 deadlines and the proposed generics tariff plan, and what they mean for reshoring.

Flat 2027 Medicare Advantage Rates Signal Tighter Budgets—and Tougher Access Ahead

CMS’s CY 2027 Medicare Advantage rates signal mounting cost pressure, setting the stage for tighter benefits, tougher contracting, and heightened access scrutiny in the months ahead.

Reducing Risk in the Pharmaceutical Cold Chain

When delays and disruptions threaten not only product integrity but patient well-being, thorough risk assessment and mitigation are essential.

Qualified Temperature-Controlled Corridors: The Future is Here

Webinar Date/Time: Tuesday, April 7, 2026 at 10 AM EDT I 3 PM GMT I 4 PM CET

LogiPharma USA 2025: Pharma Supply Chains Evolve Toward Real-Time Visibility and End-to-End Control

At LogiPharma USA, industry leaders from Tive, McKesson, and the broader healthcare logistics community discussed the sector’s transition from passive monitoring to real-time control, the growing influence of advanced therapies, and the importance of diversity and innovation in shaping the future of pharma supply chains.

Everyone Asks If You're Using AI. Who Asks You If It's Working?

Access leaders are pressed to prove AI ROI, but ConnectiveRx execs Cindy Baksh and Steve Randall argue the real work is defining "better" first, then deciding where AI fits.

Uniting for Patients: Helping More Americans Navigate, Access and Afford Health Care

Your Trusted Resource for Mission Critical Solutions

There’s a reason your facility’s most sensitive operations are called “mission critical.” Learn how ABM’s highly technical management services can take the worry out of maintaining your most specialized systems.

A Practitioner’s Guide to AI Lifecycle Management in Life Sciences

This guide outlines a proven framework, spanning process, people, and platform, to help healthcare innovators scale AI with compliance, collaboration, and clinical impact in mind.

Machine Health in Pharmaceutical Production

Predictive maintenance in pharmaceutical production can help reduce downtime and increase efficiency. Grundfos Machine Health (GMH) uses artificial intelligence (AI)-driven wireless sensors to monitor motor health in real-time, identifying potential issues. This approach not only reduces maintenance costs but also ensures compliance with industry standards.

What’s Your Cold Chain Testing Telling You?

Webinar Date/Time: Tues, Mar 31, 2026 2:00 PM EDT

How Smart Packaging and Emerging AI Tools Are Shaping the Future of Cold Chain Integrity

In a video interview with Pharma Commerce, Kirsten Newquist, Identiv’s CEO, and Mark Sawicki, PhD, Cryoport Systems’ president and CEO, explain how embedded product intelligence—paired with cautious, strategic adoption of AI—is redefining pharmaceutical cold chain reliability and supply-chain decision-making.

Beyond the Hype: GenAI’s Real Impact on Life Sciences Manufacturing

Taking stock of today's gains and tomorrow's potential for generative artificial intelligence in reshaping the industry.

How Integrated Solutions Deliver Measurable Value for Pharma Manufacturers

In the final part of her Pharma Commerce video interview, Tina Martinez, vice president and head of global products and solutions at Cencora, explains how streamlining clinical supply services, reducing fragmentation, and piloting data-driven tools like real-time adherence tracking are translating innovation into quantifiable efficiency, visibility, and commercial impact for manufacturers worldwide.

Strategies to Modernize, Future-Proof, and Secure the Healthcare Supply Chain

Ensuring that essential treatments reach patients safely and efficiently is an increasing imperative in today's pharma landscape.

340B Litigation and the Path Toward Transparent Drug Discount Programs

As pharma drug pricing debates heat up, the 340B program faces mounting challenges from outdated regulations, duplicate discounts, and limited transparency.

How One Brand Protected Market Share Amid Biosimilar Pressure

Case study on how one mature/late stage biopharmaceutical brand leveraged SamaCare’s insights and intervention platform to decrease administrative related discontinuations of their drug and maintain market share during a biosimilar release.

Multi-Indication Drug Branding in Today’s Pharmaceutical Industry

As drug development increasingly targets multiple indications, pharma companies must make strategic branding decisions—balancing regulatory requirements, market dynamics, and patient safety—to choose between single-brand or multi-brand approaches.

WISeR Spending or Unneeded Delays in Healthcare? Prior Authorizations, AI in Medicare Prompt Concerns

The new Medicare payment model aims to take down wasteful spending, but Congress and analysts point out potential problems.

How Pharma Supply Chains Can Brace for FDA’s 12-Digit NDC Standard

Matt Sample breaks down the operational hurdles and strategies for transitioning to the FDA’s new 12-digit NDC format.